Recombinant humanized IgG4 monoclonal antibody ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia1

61. Autoimmune hemolytic anemia


Clinical trials : 137 Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-005854-90-AT
(EUCTR)
11/02/202105/01/2021Investigation of the influence of ANX005 on the body of patients with primary cold agglutinin disease in terms of safety and tolerability. A Phase 2, single-center, open-label, repeat-dose study.A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary Cold Agglutinin Disease Primary Cold Agglutinin Disease (CAD);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: ANX005
INN or Proposed INN: ANX005
Other descriptive name: Recombinant humanized IgG4 monoclonal antibody
Annexon, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
6Phase 2Austria